JP2019110902A - 免疫細胞のインビトロ活性化および/または増殖の方法 - Google Patents
免疫細胞のインビトロ活性化および/または増殖の方法 Download PDFInfo
- Publication number
- JP2019110902A JP2019110902A JP2018239957A JP2018239957A JP2019110902A JP 2019110902 A JP2019110902 A JP 2019110902A JP 2018239957 A JP2018239957 A JP 2018239957A JP 2018239957 A JP2018239957 A JP 2018239957A JP 2019110902 A JP2019110902 A JP 2019110902A
- Authority
- JP
- Japan
- Prior art keywords
- immune
- immune cells
- cells
- antibody
- magnetic particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002865 immune cell Anatomy 0.000 title claims abstract description 77
- 238000000034 method Methods 0.000 title claims abstract description 42
- 230000004913 activation Effects 0.000 title claims abstract description 37
- 238000000338 in vitro Methods 0.000 title claims abstract description 27
- 239000006249 magnetic particle Substances 0.000 claims abstract description 114
- 210000004027 cell Anatomy 0.000 claims abstract description 73
- 229920001577 copolymer Polymers 0.000 claims abstract description 45
- 229920000642 polymer Polymers 0.000 claims abstract description 18
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 61
- 230000035755 proliferation Effects 0.000 claims description 30
- 239000000411 inducer Substances 0.000 claims description 27
- 230000005291 magnetic effect Effects 0.000 claims description 24
- 239000000178 monomer Substances 0.000 claims description 23
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 14
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 13
- 229910052710 silicon Inorganic materials 0.000 claims description 13
- 239000010703 silicon Substances 0.000 claims description 13
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 10
- 238000001179 sorption measurement Methods 0.000 claims description 9
- 102000002627 4-1BB Ligand Human genes 0.000 claims description 8
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 8
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 claims description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 5
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical group C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 claims description 4
- 229960002685 biotin Drugs 0.000 claims description 4
- 239000011616 biotin Substances 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- 230000003993 interaction Effects 0.000 claims description 4
- -1 iron ions Chemical class 0.000 claims description 4
- VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical compound [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 229910001429 cobalt ion Inorganic materials 0.000 claims description 3
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 210000000822 natural killer cell Anatomy 0.000 claims description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 3
- 229910001453 nickel ion Inorganic materials 0.000 claims description 3
- 210000003289 regulatory T cell Anatomy 0.000 claims description 3
- 230000001588 bifunctional effect Effects 0.000 claims 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 2
- 239000000126 substance Substances 0.000 abstract description 18
- 230000003213 activating effect Effects 0.000 abstract description 4
- 239000000696 magnetic material Substances 0.000 abstract description 2
- 230000006698 induction Effects 0.000 abstract 2
- 229920001296 polysiloxane Polymers 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 25
- 230000001939 inductive effect Effects 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 9
- 210000000612 antigen-presenting cell Anatomy 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 210000004443 dendritic cell Anatomy 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 230000005389 magnetism Effects 0.000 description 5
- 210000003071 memory t lymphocyte Anatomy 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 239000007987 MES buffer Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- MYRTYDVEIRVNKP-UHFFFAOYSA-N divinylbenzene Substances C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- 238000002619 cancer immunotherapy Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- LFQCEHFDDXELDD-UHFFFAOYSA-N tetramethyl orthosilicate Chemical compound CO[Si](OC)(OC)OC LFQCEHFDDXELDD-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 239000012930 cell culture fluid Substances 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000005294 ferromagnetic effect Effects 0.000 description 2
- 230000005307 ferromagnetism Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 230000005931 immune cell recruitment Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- BPSIOYPQMFLKFR-UHFFFAOYSA-N trimethoxy-[3-(oxiran-2-ylmethoxy)propyl]silane Chemical compound CO[Si](OC)(OC)CCCOCC1CO1 BPSIOYPQMFLKFR-UHFFFAOYSA-N 0.000 description 2
- HWSSEYVMGDIFMH-UHFFFAOYSA-N 2-[2-[2-(2-methylprop-2-enoyloxy)ethoxy]ethoxy]ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCOCCOCCOC(=O)C(C)=C HWSSEYVMGDIFMH-UHFFFAOYSA-N 0.000 description 1
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 1
- JOIPGYAFSWSMAB-UHFFFAOYSA-N CCO[Si](OCC)(OCC)CCCOCC1CO1.CCO[Si](OCC)(OCC)CCCOCC1CO1 Chemical compound CCO[Si](OCC)(OCC)CCCOCC1CO1.CCO[Si](OCC)(OCC)CCCOCC1CO1 JOIPGYAFSWSMAB-UHFFFAOYSA-N 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- PYIRCTCYUFTCEJ-UHFFFAOYSA-L [NH-]C(CC(C(NO)=O)S([O-])(=O)=O)=O.[Na+].[Na+] Chemical compound [NH-]C(CC(C(NO)=O)S([O-])(=O)=O)=O.[Na+].[Na+] PYIRCTCYUFTCEJ-UHFFFAOYSA-L 0.000 description 1
- 210000002203 alpha-beta t lymphocyte Anatomy 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 238000012674 dispersion polymerization Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000007720 emulsion polymerization reaction Methods 0.000 description 1
- 229960002089 ferrous chloride Drugs 0.000 description 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000005415 magnetization Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 229940125645 monoclonal antibody drug Drugs 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000005408 paramagnetism Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- IARLBMZSSJJOCU-UHFFFAOYSA-N sodium;1-oxidopyrrolidine-2,5-dione Chemical compound [Na+].[O-]N1C(=O)CCC1=O IARLBMZSSJJOCU-UHFFFAOYSA-N 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 238000006557 surface reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010557 suspension polymerization reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RXRIEAKKQPAUKB-UHFFFAOYSA-N trimethoxy-[3-(oxiran-2-ylmethoxy)propyl]silane Chemical group CO[Si](OC)(OC)CCCOCC1CO1.CO[Si](OC)(OC)CCCOCC1CO1 RXRIEAKKQPAUKB-UHFFFAOYSA-N 0.000 description 1
- YUYCVXFAYWRXLS-UHFFFAOYSA-N trimethoxysilane Chemical compound CO[SiH](OC)OC YUYCVXFAYWRXLS-UHFFFAOYSA-N 0.000 description 1
- 229910000859 α-Fe Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
- G01N33/54333—Modification of conditions of immunological binding reaction, e.g. use of more than one type of particle, use of chemical agents to improve binding, choice of incubation time or application of magnetic field during binding reaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/505—CD4; CD8
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2529/00—Culture process characterised by the use of electromagnetic stimulation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/10—Mineral substrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2535/00—Supports or coatings for cell culture characterised by topography
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2535/00—Supports or coatings for cell culture characterised by topography
- C12N2535/10—Patterned coating
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
102a、102b:免疫誘導物質
110:多突状コポリマーコア
112:突起物
120:ポリマー層
130:磁性体層
h:平均高さ
Claims (15)
- a) 表面が多突状であり、かつ少なくとも一種の免疫誘導物質が修飾され、内側から外側に向かってコポリマーコア、ポリマー層、磁性体層、およびシリコンベース層を含む磁性粒子を提供すること、
b) 少なくとも一種の免疫細胞を含む細胞溶液を提供すること、
c) 前記磁性粒子と前記細胞溶液とを接触させて、前記磁性粒子の前記表面上の前記少なくとも一種の免疫誘導物質により前記細胞溶液中の前記少なくとも一種の免疫細胞を活性化および/または増殖させること、
を含む、免疫細胞のインビトロ活性化および/または増殖の方法。 - 前記コポリマーコアの表面が複数の不規則な形状の突起物を含む、請求項1に記載の免疫細胞のインビトロ活性化および/または増殖の方法。
- 前記複数の突起物の平均高さは100nm〜5000nmである、請求項2に記載の免疫細胞のインビトロ活性化および/または増殖の方法。
- 前記磁性粒子の平均直径は1μm〜50μmである、請求項1に記載の免疫細胞のインビトロ活性化および/または増殖の方法。
- 前記免疫細胞がT細胞、NK細胞またはそれらの組み合わせを含む、請求項1に記載の免疫細胞のインビトロ活性化および/または増殖の方法。
- 前記免疫細胞が調節性T細胞を含む、請求項5に記載の免疫細胞のインビトロ活性化および/または増殖の方法。
- 前記免疫細胞が、αβT細胞、γδT細胞またはそれらの組み合わせを含む、請求項6に記載の免疫細胞のインビトロ活性化および/または増殖の方法。
- 前記少なくとも一種の免疫誘導物質は、抗CD3抗体、抗CD28抗体、抗TCRγ/δ抗体、抗CD83抗体、抗CD137抗体、4−1BBL、抗CD2抗体、抗CD335抗体、またはそれらの組み合わせを含む、請求項1に記載の免疫細胞のインビトロ活性化および/または増殖の方法。
- 前記少なくとも一種の免疫誘導物質が前記磁性粒子の前記表面に修飾される方法は、非共有結合、共有結合、アビジン‐ビオチン相互作用、静電吸着、疎水性吸着またはそれらの組み合わせを含む、請求項1に記載の免疫細胞のインビトロ活性化および/または増殖の方法。
- 前記コポリマーコアが、単官能モノマーと二官能モノマーとを共重合して得られるコポリマーを含む、請求項1に記載の免疫細胞のインビトロ活性化および/または増殖の方法。
- 前記単官能モノマーに対する前記二官能モノマーの体積百分率が0.4%〜2%である、請求項10に記載の免疫細胞のインビトロ活性化および/または増殖の方法。
- 前記コポリマーコアがスチレン/ジビニルベンゼンコポリマー、メチルメタクリレート/トリエチレングリコールジメタクリレートコポリマー、メチルメタクリレート/エチレングリコールジメタクリレートコポリマー、スチレン/トリエチレングリコールジメタクリレートコポリマー、スチレン/エチレングリコールジメタクリレートコポリマーまたはメチルメタクリレート/ジビニルベンゼンコポリマーを含む、請求項1に記載の免疫細胞のインビトロ活性化および/または増殖の方法。
- 前記ポリマー層がカルボキシル基、アミン基またはそれらの組み合わせを含む、請求項1に記載の免疫細胞のインビトロ活性化および/または増殖の方法。
- 前記磁性体層が鉄イオン(Fe2+)、コバルトイオン(Co2+)、ニッケルイオン(Ni2+)またはそれらの組み合わせを含む、請求項1に記載の免疫細胞のインビトロ活性化および/または増殖の方法。
- 前記シリコンベース層の厚さが少なくとも1nm〜50nmである、請求項1に記載の免疫細胞のインビトロ活性化および/または増殖の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762609345P | 2017-12-22 | 2017-12-22 | |
US62/609,345 | 2017-12-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019110902A true JP2019110902A (ja) | 2019-07-11 |
JP6744906B2 JP6744906B2 (ja) | 2020-08-19 |
Family
ID=65365762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018239957A Active JP6744906B2 (ja) | 2017-12-22 | 2018-12-21 | 免疫細胞のインビトロ活性化および/または増殖の方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US11859176B2 (ja) |
EP (1) | EP3502238A1 (ja) |
JP (1) | JP6744906B2 (ja) |
CN (1) | CN109957544B (ja) |
TW (1) | TWI699218B (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111733154B (zh) * | 2020-04-30 | 2022-11-04 | 和也健康科技有限公司 | 磁场处理的免疫细胞及其用途 |
WO2021231797A1 (en) * | 2020-05-13 | 2021-11-18 | Rapa Therapeutics, Llc | Treatment or prevention of pro-inflammatory diseases or conditions using induced regulatory t (itreg) cells |
EP4019973B1 (en) * | 2020-12-28 | 2024-05-29 | Industrial Technology Research Institute | Detection method of multiple analytes |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006275600A (ja) * | 2005-03-28 | 2006-10-12 | Jsr Corp | 磁性粒子およびその製造方法、ならびに生化学用担体 |
JP2008164488A (ja) * | 2006-12-28 | 2008-07-17 | Jsr Corp | 磁性粒子およびその製造方法、ならびに生化学用担体 |
US20090017518A1 (en) * | 2007-07-11 | 2009-01-15 | Industrial Technology Research Institute | Magnetic particles and fabrication method thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
IL151287A0 (en) | 2000-02-24 | 2003-04-10 | Xcyte Therapies Inc | A method for stimulation and concentrating cells |
EP1241249A1 (en) * | 2001-03-12 | 2002-09-18 | Gerold Schuler | CD4+CD25+regulatory T cells from human blood |
US20040058445A1 (en) | 2001-04-26 | 2004-03-25 | Ledbetter Jeffrey Alan | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB |
GB0603081D0 (en) | 2006-02-15 | 2006-03-29 | Dynal Biotech Asa Oslo | Method |
JP4281071B1 (ja) | 2008-07-10 | 2009-06-17 | 学校法人兵庫医科大学 | Vγ9Vδ2T細胞の増殖剤、活性化Vγ9Vδ2T細胞の製造方法およびこれらの利用 |
US9114100B2 (en) | 2010-05-17 | 2015-08-25 | Duke University | Methods of treatment using ex vivo expansion of cord blood T cells |
WO2013036585A1 (en) | 2011-09-06 | 2013-03-14 | The Trustees Of The University Of Pennsylvania | Activation and expansion of t cell subsets using biocompatible solid substrates with tunable rigidity |
EP2711418B1 (en) | 2012-09-25 | 2017-08-23 | Miltenyi Biotec GmbH | Method for polyclonal stimulation of T cells by flexible nanomatrices |
CN104278012B (zh) | 2014-10-11 | 2016-11-23 | 湖南赛诺生物科技股份有限公司 | 一种成人调节性t细胞体外扩增培养基及其使用方法 |
CN104651309A (zh) | 2015-02-04 | 2015-05-27 | 中山大学孙逸仙纪念医院 | 人外周血CD4+CD25+Foxp3+调节性T细胞的分选扩增方法 |
CN105624107B (zh) * | 2015-09-21 | 2020-06-12 | 杭州优善生物科技有限公司 | 一种多种淋巴细胞亚群的扩增方法及其应用 |
-
2018
- 2018-12-21 TW TW107146291A patent/TWI699218B/zh active
- 2018-12-21 EP EP18215030.0A patent/EP3502238A1/en active Pending
- 2018-12-21 JP JP2018239957A patent/JP6744906B2/ja active Active
- 2018-12-21 CN CN201811574093.3A patent/CN109957544B/zh active Active
- 2018-12-21 US US16/228,763 patent/US11859176B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006275600A (ja) * | 2005-03-28 | 2006-10-12 | Jsr Corp | 磁性粒子およびその製造方法、ならびに生化学用担体 |
JP2008164488A (ja) * | 2006-12-28 | 2008-07-17 | Jsr Corp | 磁性粒子およびその製造方法、ならびに生化学用担体 |
US20090017518A1 (en) * | 2007-07-11 | 2009-01-15 | Industrial Technology Research Institute | Magnetic particles and fabrication method thereof |
Non-Patent Citations (3)
Title |
---|
ANNETTE TRICKETT ET. AL.: "T cell stimulation and expansion using anti-CD3/CD28 beads", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 275, JPN6020003261, 2003, pages 251 - 255, XP004416755, ISSN: 0004202938, DOI: 10.1016/S0022-1759(03)00010-3 * |
D. TESCHNER ET.AL.: "In Vitro Stimulation and Expansion of Human Tumour-Reactive CD8+ Cytotoxic T Lymphocytes by Anti-CD3", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 74, JPN6020003263, 2011, pages 155 - 164, XP055452404, ISSN: 0004202939, DOI: 10.1111/j.1365-3083.2011.02564.x * |
WAYNE R. GODFREY ET. AL.: "In vitro-expanded human CD4+CD25+ T-regulatory cells can markedly inhibit allogeneic dendritic cell-", BLOOD, vol. 104, no. 2, JPN6020003265, 2004, pages 453 - 461, XP002457226, ISSN: 0004202940, DOI: 10.1182/blood-2004-01-0151 * |
Also Published As
Publication number | Publication date |
---|---|
CN109957544A (zh) | 2019-07-02 |
EP3502238A1 (en) | 2019-06-26 |
TWI699218B (zh) | 2020-07-21 |
TW201927289A (zh) | 2019-07-16 |
CN109957544B (zh) | 2023-09-12 |
JP6744906B2 (ja) | 2020-08-19 |
US20190203195A1 (en) | 2019-07-04 |
US11859176B2 (en) | 2024-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190071640A1 (en) | Methods and materials for the generation of regulatory t cells | |
JP6216793B2 (ja) | 可動性ナノマトリックスによるt細胞のポリクローナル刺激方法 | |
Casati et al. | Clinical-scale selection and viral transduction of human naive and central memory CD8+ T cells for adoptive cell therapy of cancer patients | |
US9790467B2 (en) | Methods and compositions for activation or expansion of T lymphocytes | |
CN110072993B (zh) | 由浮力实现的分离方法和系统 | |
JP6744906B2 (ja) | 免疫細胞のインビトロ活性化および/または増殖の方法 | |
CN110891969B (zh) | 调节免疫细胞的方法和组合物 | |
JP2017529080A (ja) | 抗原特異的t細胞を同定、濃縮、及び/または増殖させるための試薬及び方法 | |
ES2612918T3 (es) | Método para inducir la proliferación de células asesinas naturales por nanomatrices móviles | |
JP2014533957A (ja) | 細胞分離方法 | |
JP7218309B2 (ja) | T細胞の増殖方法及び用途 | |
CN113832102B (zh) | Cd3/cd28/dll4磁珠及其制备方法和应用 | |
EP2886645A1 (en) | Expansion of human T cells in vitro by bead-bound conventional anti-CD28 monoclonal antibodies | |
JP5994144B2 (ja) | Nk細胞培養容器及びnk細胞培養方法 | |
US20220195414A1 (en) | Improved Manufacturing Procedures for Cell Based Therapies | |
WO2016151741A1 (ja) | Nk細胞培養容器及びnk細胞培養方法 | |
EP4165168A1 (en) | Methods for preparation of immune cells | |
US20240150713A1 (en) | Method for Producing Human Chimeric Antigen Receptor T-Cell Population Enriched with Stem Cell-like Memory T-Cells | |
CN117987472A (zh) | 生产富含干细胞样中央记忆表型t细胞的人类嵌合抗原受体t细胞的方法 | |
CN118165933A (zh) | 组合物、提高cd39-cd69-t细胞比例的方法 | |
JP2021534747A (ja) | アポトーシス感受性細胞のモジュレーション | |
WO2020099384A1 (en) | In vitro production of high affinity monoclonal antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190329 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190329 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200120 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200204 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200424 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200605 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200707 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200731 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6744906 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |